Interestingly, hypercholesterolemia associated with nephrotic syndrome can be ameliorated by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9), a posttranscriptional regulator of the LDL receptor. Here, LDLR is linked to Hypercholesterolemia.